Regeneron Pharmaceuticals

Biotechnology / diversified

REGN · Nasdaq · United States

Share price · REGN

$945.53+135.29 (+16.70%) 3M

close as of 2026-11-18 · 24h delayed · vol 705K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when REGN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026-4.4%
  2. 2 Nov 2026+3.6%
  3. 30 Oct 2026+13.3%
  4. 28 Sep 2026-4.5%
  5. 31 Jul 2026+3.3%
  6. 30 Jul 2026+6.2%
  7. 18 May 2026-9.8%
  8. 29 Apr 2026-6.2%
  9. 23 Apr 2026+2.6%
  10. 20 Nov 2025+4.9%

Share of unusual movement by asset

For each asset, the share of REGN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
dupilumab (Dupixent)
events and moves
2710%
Cemiplimab
events and moves
94%
Aflibercept (Eylea)
events and moves
4shown from 8 days
Fianlimab
events and moves
4shown from 8 days
garetosmab (Pasatru)
events and moves
3shown from 8 days
Linvoseltamab
events and moves
3shown from 8 days
Cemdisiran
events and moves
3shown from 8 days
olatorepatide
events and moves
2shown from 8 days
Odronextamab
events and moves
2shown from 8 days
trevogrumab
events and moves
1shown from 8 days
Pozelimab (Veopoz)
events and moves
1shown from 8 days
ALN-CIDEB
events and moves
1shown from 8 days
Freneslerbart/mevonlerbart
events and moves
1shown from 8 days
REGN20423
events and moves
1shown from 8 days
Ubamatamab
events and moves
1shown from 8 days
Baloncibart
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—15%
Other company news (earnings, financing, releases naming no asset)—18%
Sessions with no dated event—52%

Assets

(51 total)
51Total Assets
8Approved
10Phase 3 / Filed
33Phase 1–2 / Early
50Diseases
Quick filter:
Showing 51 of 51 assets
Target & Modality
Approved
VEGF-A · VEGF-A / VEGF-B / Placental Growth Factor (PlGF)Protein / enzyme therapeutic
Age-Related Macular DegenerationDiabetic Macular Edema
Wet Age-Related Macular Degeneration
Alirocumab(Praluent)
Approved
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular DiseaseHomozygous Familial Hypercholesterolemia
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerMelanoma
dupilumab(Dupixent)
Approved
IL-4R-alphaMonoclonal antibody
Atopic DermatitisChronic Obstructive Pulmonary DiseaseAsthmaChronic Spontaneous UrticariaPrurigo NodularisEosinophilic Esophagitis
Evinacumab(Evkeeza)
Approved
ANGPTL3Monoclonal antibody
Homozygous Familial Hypercholesterolemia
garetosmab(Pasatru)
Approved
Activin AMonoclonal antibody
ObesityFibrodysplasia Ossificans Progressiva
Approved
BCMA x CD3Multispecific antibody
Multiple Myeloma
Approved
IL-6 receptorMonoclonal antibody
Rheumatoid ArthritisSystemic Juvenile Idiopathic Arthritis
Phase 3
CIDEBRNA / oligonucleotide
MASH / NASH
Phase 3
Complement C5RNA / oligonucleotide
Age-Related Macular DegenerationMyasthenia Gravis
Generalized Myasthenia Gravis
Phase 3
Factor XIMonoclonal antibody
Venous Thromboembolism
Phase 3
LAG-3Monoclonal antibody
Melanoma
Phase 3
Fel d 1 (major cat allergen protein)Monoclonal antibody
AsthmaAllergic ConjunctivitisCat Allergy
Phase 3
Leptin receptorMonoclonal antibody
ObesityGeneralized Lipodystrophy
Phase 3
Transthyretin (TTR)Gene therapy / editing
Transthyretin-Mediated Amyloidosis
Transthyretin Amyloidosis with Cardiomyopathy

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(86 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Alirocumab · PraluentPhase 2Hypercholesterolemia
Est. primary completion 2026-12-29 · NCT07477704 · CT.gov ↗
What to watch
2027 (17)
January 2027 (1)
Cemiplimab + FianlimabPhase 3Melanoma
Est. primary completion 2027-01-15 · NCT05608291 · CT.gov ↗
What to watch
February 2027 (2)
Cenvacibart + AmrecibartPhase 2Atrial Fibrillation (AF)
Est. primary completion 2027-02-09 · NCT07175428 · CT.gov ↗
What to watch
CenvacibartPhase 3Venous Thromboembolism (VTE)
Est. primary completion 2027-02-20 · NCT07015905 · CT.gov ↗
What to watch
March 2027 (3)
Cemiplimab + FianlimabPhase 3Melanoma
Est. primary completion 2027-03-22 · NCT06246916 · CT.gov ↗
What to watch
olatorepatidePhase 3Type 2 Diabetes
Est. primary completion 2027-03-30 · NCT07156500 · CT.gov ↗
What to watch
olatorepatidePhase 3Type 2 Diabetes
Est. primary completion 2027-03-30 · NCT07156539 · CT.gov ↗
What to watch
May 2027 (2)
Cemiplimab + UbamatamabPhase 1/2Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer …
Est. primary completion 2027-05-10 · NCT03564340 · CT.gov ↗
What to watch
CenvacibartPhase 3Symptomatic Venous Thromboembolism (VTE)
Est. primary completion 2027-05-17 · NCT07213778 · CT.gov ↗
What to watch
June 2027 (2)
dupilumab · DupixentPhase 3Pruritus
Est. primary completion 2027-06-02 · NCT05263206 · CT.gov ↗
What to watch
mibavademabPhase 3Monogenic Obesity
Est. primary completion 2027-06-18 · NCT07220772 · CT.gov ↗
What to watch
July 2027 (1)
DavutamigPhase 1/2NSCLC
Est. primary completion 2027-07-06 · NCT04077099 · CT.gov ↗
What to watch
August 2027 (2)
ALN-PNPPhase 1/2Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Est. primary completion 2027-08-10 · NCT05648214 · CT.gov ↗
What to watch
ALN-CIDEBPhase 1/2Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Est. primary completion 2027-08-17 · NCT06836609 · CT.gov ↗
What to watch
September 2027 (1)
Cemiplimab + FianlimabPhase 2/3Advanced Non-Small Cell Lung Cancer
Est. primary completion 2027-09-28 · NCT05785767 · CT.gov ↗
What to watch
October 2027 (1)
dupilumab · DupixentPhase 3Prurigo Nodularis
Est. primary completion 2027-10-28 · NCT06293053 · CT.gov ↗
What to watch
November 2027 (2)
Cemiplimab + NezastomigPhase 1/2Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Est. primary completion 2027-11-15 · NCT03972657 · CT.gov ↗
What to watch
VonsetamigPhase 1/2Chronic Kidney Disease (CKD)
Est. primary completion 2027-11-22 · NCT05092347 · CT.gov ↗
What to watch
2028 (24)
January 2028 (4)
CemiplimabPhase 3Cutaneous Squamous Cell Carcinoma
Est. primary completion 2028-01-07 · NCT03969004 · CT.gov ↗
What to watch
olatorepatidePhase 2Overweight or Obesity
Est. primary completion 2028-01-21 · NCT07685808 · CT.gov ↗
What to watch
CemiplimabPhase 2Advanced Non-Small Cell Lung Cancer
Est. primary completion 2028-01-26 · NCT05557591 · CT.gov ↗
What to watch
mibavademabPhase 2Functional Hypothalamic Amenorrhea, FHA
Est. primary completion 2028-01-28 · NCT07235917 · CT.gov ↗
What to watch
February 2028 (2)
VasigrobartPhase 2Pulmonary Arterial Hypertension (PAH)
Est. primary completion 2028-02-27 · NCT07318597 · CT.gov ↗
What to watch
OdronextamabPhase 3Follicular Lymphoma (FL)
Est. primary completion 2028-02-29 · NCT06091254 · CT.gov ↗
What to watch
March 2028 (2)
SarilumabPhase 2Juvenile Idiopathic Arthritis
Est. primary completion 2028-03-01 · NCT02991469 · CT.gov ↗
What to watch
OdronextamabPhase 3Diffuse Large B-cell Lymphoma (DLBCL)
Est. primary completion 2028-03-30 · NCT06091865 · CT.gov ↗
What to watch
April 2028 (1)
Rapirosiran (ALN-HSD)Phase 2Metabolic Dysfunction-Associated SteatoHepatitis (MASH)
Est. primary completion 2028-04-27 · NCT05519475 · CT.gov ↗
What to watch
May 2028 (3)
dupilumab · DupixentPhase 3Dermatitis Atopic
Est. primary completion 2028-05-02 · NCT07919899 · CT.gov ↗
What to watch
mibavademabPhase 3Generalized Lipodystrophy
Est. primary completion 2028-05-19 · NCT07220785 · CT.gov ↗
What to watch
OdronextamabPhase 3B-Cell Non-Hodgkin Lymphoma (B-NHL)
Est. primary completion 2028-05-29 · NCT06230224 · CT.gov ↗
What to watch
June 2028 (3)
Cemiplimab + FianlimabPhase 2Head and Neck Squamous Cell Carcinoma (HNSCC)
Est. primary completion 2028-06-04 · NCT06769698 · CT.gov ↗
What to watch
dupilumab · DupixentPhase 3Eosinophilic Esophagitis (EoE)
Est. primary completion 2028-06-19 · NCT07112378 · CT.gov ↗
What to watch
Cemiplimab + Fianlimab + Ubamatamab + REGN10597Phase 2Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Est. primary completion 2028-06-30 · NCT06787612 · CT.gov ↗
What to watch
July 2028 (1)
Pozelimab · Veopoz + CemdisiranPhase 3Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Est. primary completion 2028-07-31 · NCT06541704 · CT.gov ↗
What to watch
August 2028 (1)
LinvoseltamabPhase 1/2Relapsed/Refractory Systemic Light Chain Amyloidosis
Est. primary completion 2028-08-20 · NCT06292780 · CT.gov ↗
What to watch
October 2028 (3)
Pozelimab · Veopoz + CemdisiranPhase 3Paroxysmal Nocturnal Hemoglobinuria
Est. primary completion 2028-10-10 · NCT05744921 · CT.gov ↗
What to watch
ALN-ANG3 + Evinacumab · EvkeezaPhase 2Diabetic Kidney Disease (DKD)
Est. primary completion 2028-10-13 · NCT07271186 · CT.gov ↗
What to watch
SarilumabPhase 1/2Rheumatoid Arthritis
Est. primary completion 2028-10-26 · NCT07704580 · CT.gov ↗
What to watch
November 2028 (2)
Cemiplimab + Fianlimab + Ubamatamab + REGN5668Phase 1/2Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
Est. primary completion 2028-11-08 · NCT04590326 · CT.gov ↗
What to watch
olatorepatidePhase 2Hidradenitis Suppurativa
Est. primary completion 2028-11-24 · NCT07830329 · CT.gov ↗
What to watch
December 2028 (2)
olatorepatidePhase 3Overweight or Obesity Without Diabetes
Est. primary completion 2028-12-19 · NCT07896265 · CT.gov ↗
What to watch
dupilumab · DupixentPhase 3Wheezing, Asthma
Est. primary completion 2028-12-21 · NCT06191315 · CT.gov ↗
What to watch
2029 (16)
January 2029 (1)
ALN-CIDEBPhase 2Metabolic Dysfunction-Associated Steatohepatitis, MASH
Est. primary completion 2029-01-29 · NCT07631637 · CT.gov ↗
What to watch
March 2029 (2)
ALN-CIDEBPhase 3Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Est. primary completion 2029-03-03 · NCT07854782 · CT.gov ↗
What to watch
Cenvacibart + AmrecibartPhase 3Atrial Fibrillation (AF)
Est. primary completion 2029-03-28 · NCT07430956 · CT.gov ↗
What to watch
May 2029 (3)
ALN-CIDEBPhase 2Alcohol-Associated Liver Disease, ALD
Est. primary completion 2029-05-07 · NCT07933328 · CT.gov ↗
What to watch
LinvoseltamabPhase 3Relapsed and/or Refractory Multiple Myeloma (RRMM)
Est. primary completion 2029-05-21 · NCT07222761 · CT.gov ↗
What to watch
Freneslerbart/mevonlerbartPhase 3Allergic Conjunctivitis
Est. primary completion 2029-05-31 · NCT07675811 · CT.gov ↗
What to watch
June 2029 (2)
SarilumabPhase 3Polymyalgia Rheumatica
Est. primary completion 2029-06-04 · NCT07286214 · CT.gov ↗
What to watch
Cenvacibart + AmrecibartPhase 3Venous Thromboembolism (VTE)
Est. primary completion 2029-06-25 · NCT07697599 · CT.gov ↗
What to watch
July 2029 (1)
OdronextamabPhase 3Follicular Lymphoma (FL)
Est. primary completion 2029-07-29 · NCT06097364 · CT.gov ↗
What to watch
August 2029 (1)
Cenvacibart + AmrecibartPhase 3Peripheral Artery Disease (PAD)
Est. primary completion 2029-08-18 · NCT07318610 · CT.gov ↗
What to watch
September 2029 (2)
CenvacibartPhase 3Atrial Fibrillation (AF)
Est. primary completion 2029-09-11 · NCT07626411 · CT.gov ↗
What to watch
REGN22530Phase 1/2Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Est. primary completion 2029-09-14 · NCT07675824 · CT.gov ↗
What to watch
November 2029 (2)
OdronextamabPhase 1/2Diffuse Large B-Cell Lymphoma (DLBCL)
Est. primary completion 2029-11-01 · NCT07887750 · CT.gov ↗
What to watch
ALN-CFBPhase 1/2Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia
Est. primary completion 2029-11-29 · NCT07187401 · CT.gov ↗
What to watch
December 2029 (2)
Cemiplimab + Marlotamig + REGN10597Phase 2Non Small Cell Lung Cancer, NSCLC
Est. primary completion 2029-12-04 · NCT06465329 · CT.gov ↗
What to watch
CenvacibartPhase 3Secondary Stroke
Est. primary completion 2029-12-15 · NCT07876492 · CT.gov ↗
What to watch
2030 (12)
January 2030 (3)
Cemiplimab + FianlimabPhase 2/3Non-small Cell Lung Cancer
Est. primary completion 2030-01-16 · NCT05800015 · CT.gov ↗
What to watch
Pozelimab · Veopoz + CemdisiranPhase 3Paroxysmal Nocturnal Hemoglobinuria
Est. primary completion 2030-01-18 · NCT07154745 · CT.gov ↗
What to watch
CenvacibartPhase 3Cancer-Associated Thrombosis (CAT)
Est. primary completion 2030-01-23 · NCT07410117 · CT.gov ↗
What to watch
February 2030 (1)
Cemiplimab + REGN10597Phase 1/2Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors
Est. primary completion 2030-02-03 · NCT06413680 · CT.gov ↗
What to watch
March 2030 (2)
ALN-PNPPhase 2Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Est. primary completion 2030-03-15 · NCT07527910 · CT.gov ↗
What to watch
Olsutamig + NezastomigPhase 1/2Metastatic Castration-resistant Prostate Cancer
Est. primary completion 2030-03-28 · NCT05125016 · CT.gov ↗
What to watch
May 2030 (1)
CemiplimabPhase 3Cutaneous Squamous Cell Carcinoma (CSCC)
Est. primary completion 2030-05-03 · NCT06585410 · CT.gov ↗
What to watch
June 2030 (1)
Marlotamig + UbamatamabPhase 2Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Carcinoma Non Small Cell Lung
Est. primary completion 2030-06-10 · NCT07154290 · CT.gov ↗
What to watch
July 2030 (1)
garetosmab · PasatruPhase 3Fibrodysplasia Ossificans Progressiva, FOP
Est. primary completion 2030-07-08 · NCT07559513 · CT.gov ↗
What to watch
October 2030 (2)
Cemiplimab + FianlimabPhase 2Melanoma
Est. primary completion 2030-10-09 · NCT06848088 · CT.gov ↗
What to watch
Cemiplimab + Olsutamig + REGN15505Phase 1/2Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
Est. primary completion 2030-10-27 · NCT07594106 · CT.gov ↗
What to watch
November 2030 (1)
Cemiplimab + FianlimabPhase 2Locally Advanced Basal Cell Carcinoma
Est. primary completion 2030-11-13 · NCT07808515 · CT.gov ↗
What to watch
2031 (4)
February 2031 (1)
ALN-6457Phase 1/2Prion Disease
Est. primary completion 2031-02-27 · NCT07832370 · CT.gov ↗
What to watch
April 2031 (1)
OdronextamabPhase 3Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Est. primary completion 2031-04-30 · NCT06149286 · CT.gov ↗
What to watch
July 2031 (2)
CenvacibartPhase 3Venous Thromboembolism (VTE)
Est. primary completion 2031-07-18 · NCT07493304 · CT.gov ↗
What to watch
NezastomigPhase 1/2Metastatic Castration-Resistant Prostate Cancer, mCRPC
Est. primary completion 2031-07-28 · NCT07850921 · CT.gov ↗
What to watch
2032 (3)
March 2032 (1)
ALN-SODPhase 1/2Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Est. primary completion 2032-03-21 · NCT06351592 · CT.gov ↗
What to watch
May 2032 (1)
LinvoseltamabPhase 2Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM)
Est. primary completion 2032-05-18 · NCT06140524 · CT.gov ↗
What to watch
August 2032 (1)
Cemiplimab + FianlimabPhase 1/2High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma
Est. primary completion 2032-08-27 · NCT07567469 · CT.gov ↗
What to watch
2033 (6)
January 2033 (1)
LinvoseltamabPhase 2Smoldering Multiple Myeloma (SMM)
Est. primary completion 2033-01-25 · NCT05955508 · CT.gov ↗
What to watch
March 2033 (1)
LinvoseltamabPhase 1/2Multiple Myeloma
Est. primary completion 2033-03-30 · NCT03761108 · CT.gov ↗
What to watch
April 2033 (1)
LinvoseltamabPhase 3Relapsed Refractory Multiple Myeloma (RRMM)
Est. primary completion 2033-04-19 · NCT05730036 · CT.gov ↗
What to watch
July 2033 (1)
LinvoseltamabPhase 3High Risk Smoldering Multiple Myeloma (HR-SMM)
Est. primary completion 2033-07-27 · NCT07393282 · CT.gov ↗
What to watch
September 2033 (1)
Linvoseltamab + REGN17372Phase 1/2Relapsed Refractory Multiple Myeloma (RRMM)
Est. primary completion 2033-09-30 · NCT07455851 · CT.gov ↗
What to watch
November 2033 (1)
Linvoseltamab + REGN7945Phase 1/2Relapsed/Refractory Multiple Myeloma
Est. primary completion 2033-11-11 · NCT06669247 · CT.gov ↗
What to watch
2034 (1)
August 2034 (1)
REGV131-LNP1265Phase 1/2Hemophilia B
Est. primary completion 2034-08-14 · NCT06379789 · CT.gov ↗
What to watch
2035 (2)
July 2035 (1)
LinvoseltamabPhase 3Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA
Est. primary completion 2035-07-25 · NCT07901725 · CT.gov ↗
What to watch
November 2035 (1)
LinvoseltamabPhase 1/2Multiple Myeloma
Est. primary completion 2035-11-02 · NCT05828511 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(34)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

November 2026FDA action dateCemdisiranCemdisiran PDUFA target action date (generalized myasthenia gravis)
US, FDA · FDA · Source ↗
February 2027FDA action dateOdronextamabFDA decision on the odronextamab BLA in relapsed/refractory DLBCL expected February 2027
US, FDA · Source ↗
March 2027FDA action dateCemiplimabFDA decision on the Libtayo alternative-dosing sBLA expected March 2027
US, FDA · Source ↗

Recent

18 November 2026ApprovalCemdisiranFDA approves Livsayis (cemdisiran) for gMG
US, FDA · Source ↗
17 November 2026ApprovalCemiplimabEuropean Commission approves an extended Libtayo dosing schedule (700 mg every six weeks) and shorter infusion
EU, European Commission · Source ↗
30 October 2026Topline resultBaloncibartPhase 2 sepsis-induced hypotension study missed primary endpoint
1 October 2026Topline resulttrevogrumabCOURAGE Phase 2 lower-dose 52-week results
Regeneron Pharmaceuticals · Source ↗
19 August 2026ApprovalgaretosmabFDA approves Pasatru (garetosmab-grts) for FOP
US, FDA · Source ↗
August 2026FDA action dategaretosmabFDA target action date August 2026
US, FDA · Source ↗
22 June 2026Filing acceptedCemdisiranFDA accepts cemdisiran NDA for generalized myasthenia gravis (priority review)
US, FDA · Regeneron Pharmaceuticals · Source ↗
22 June 2026Filing acceptedCemdisiranEMA accepts cemdisiran marketing authorisation application for generalized myasthenia gravis
EU, EMA · Regeneron Pharmaceuticals · Source ↗
June 2026Filing acceptedolatorepatideNMPA accepts olatorepatide NDA
CN, NMPA · Hansoh Pharma · Source ↗
17 May 2026Topline resultCemiplimabPhase 3 of fianlimab plus cemiplimab vs pembrolizumab in first-line melanoma (NCT05352672) missed its PFS primary endpoint
May 2026Topline resultFianlimabPhase 3 fianlimab plus Libtayo versus pembrolizumab in first-line melanoma missed its PFS primary endpoint
22 April 2026ApprovaldupilumabFDA approves Dupixent for CSU in children aged 2 to 11
US, FDA · Source ↗

The 12 most recent of 31 past events are shown.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$5.1B$1.8B$3.7B+ $5.6B short-term inv.—$1.8B operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$4.3B$1.6B$2.5B+ $5.5B short-term inv.—$813M operating cash flowreport ↗
2026-Q1$3.6B$1.5B$3.0B+ $5.8B short-term inv.—$1.1B operating cash flowreport ↗
2025-Q3$3.8B$1.5B$2.5B+ $5.9B short-term inv.—$1.6B operating cash flowreport ↗
2025-Q2$3.7B$1.4B$2.0B+ $5.5B short-term inv.—$1.1B operating cash flowreport ↗
2025-Q1$3.0B$1.3B$3.1B+ $5.3B short-term inv.—$1.0B operating cash flowreport ↗
2024-Q3$3.7B$1.3B$2.0B+ $7.8B short-term inv.—$1.3B operating cash flowreport ↗
2024-Q2$3.5B$1.2B$1.9B+ $7.9B short-term inv.—$354M operating cash flowreport ↗
2024-Q1$3.1B$1.2B$2.6B+ $7.9B short-term inv.—$1.5B operating cash flowreport ↗
2023-Q3$3.4B$1.1B$2.2B+ $7.8B short-term inv.—$1.1B operating cash flowreport ↗
2023-Q2$3.2B$1.1B$1.9B+ $7.0B short-term inv.—$1.0B operating cash flowreport ↗
2023-Q1$3.2B$1.1B$3.9B+ $5.0B short-term inv.—$1.4B operating cash flowreport ↗
2022-Q3$2.9B$911M$3.5B+ $3.5B short-term inv.—$629M operating cash flowreport ↗
2022-Q2$2.9B$794M$3.4B+ $4.2B short-term inv.—$564M operating cash flowreport ↗
2022-Q1$3.0B$844M$3.4B+ $3.7B short-term inv.—$2.1B operating cash flowreport ↗
2021-Q3$3.5B$665M$3.4B+ $2.4B short-term inv.—$3.4B operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$14.3B$5.9B$3.1B+ $5.5B short-term inv.—$5.0B operating cash flowreport ↗

Regeneron reported full-year 2025 revenue of $14,342.9M, up 1.0% YoY, with R&D spend of $5,850.2M, up 14.0% YoY. The company ended the period with cash and equivalents of $3,123.7M and reported net income of $4,504.9M.

The filing did not include financial guidance. Key clinical and regulatory developments included FDA approvals for EYLEA HD in retinal vein occlusion and an every-four-week dosing option, FDA and EC approvals for Lynozyfic in relapsed/refractory multiple myeloma, and FDA approval of Dupixent for bullous pemphigoid. Regeneron also disclosed complete response letters for the EYLEA HD pre-filled syringe and odronextamab in follicular lymphoma related to a manufacturing site inspection, as well as positive Phase 3 results for itepekimab in COPD, garetosmab in fibrodysplasia ossificans progressiva, cemdisiran in myasthenia gravis, and allergy immunotherapy candidates.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$14.2B$5.1B$2.5B+ $6.5B short-term inv.—$4.4B operating cash flowreport ↗
2023-FY$13.1B$4.4B$2.7B+ $8.1B short-term inv.—$4.6B operating cash flowreport ↗
2022-FY$12.2B$3.6B$3.1B+ $4.6B short-term inv.—$5.0B operating cash flowreport ↗
2021-FY$16.1B$2.9B$2.9B+ $2.8B short-term inv.—$7.1B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 166 sales ($64.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17SING GEORGE L · directorOpen-market sale176$956.96$168KForm 4
2026-11-17MURPHY ANDREW J · Co-Chief Scientific OfficerOpen-market sale93$949.69$88KForm 4
2026-11-17SING GEORGE L · directorOpen-market sale359$957.49$344KForm 4
2026-11-17MURPHY ANDREW J · Co-Chief Scientific OfficerOpen-market sale74$950.61$70KForm 4
2026-11-17SING GEORGE L · directorOpen-market sale465$958.11$446KForm 4
2026-11-17MURPHY ANDREW J · Co-Chief Scientific OfficerOpen-market sale298$951.75$284KForm 4
2026-11-17MURPHY ANDREW J · Co-Chief Scientific OfficerOpen-market sale220$952.75$210KForm 4
2026-11-17MURPHY ANDREW J · Co-Chief Scientific OfficerOpen-market sale671$953.69$640KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1,378 reporting institutions held 87.8M shares ($64.7B, 85.2% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.8,947,735$6.9B
2VANGUARD CAPITAL MANAGEMENT LLC6,654,913$5.1B
3STATE STREET CORP4,664,478$3.6B
4Dodge & Cox4,458,238$3.4B
5JPMORGAN CHASE & CO4,311,806$3.2B
6FRANKLIN RESOURCES INC2,722,071$2.1B
7GEODE CAPITAL MANAGEMENT, LLC2,607,732$2.0B
8Nuveen, LLC2,065,064$1.6B
9LOOMIS SAYLES & CO L P1,912,310$1.5B
10WELLINGTON MANAGEMENT GROUP LLP1,837,459$1.4B
11Invesco Ltd.1,724,478$1.3B
12VANGUARD PORTFOLIO MANAGEMENT LLC1,720,774$1.3B
13FMR LLC1,518,192$1.2B
14Capital World Investors1,419,000$1.1B
15MORGAN STANLEY1,319,329$1.0B